BioXcel Therapeutics has hired Matt Wiley as its Chief Commercial Officer.
FREMONT, CA: “We are pleased to welcome Matt to our management team, as we prepare for our first potential approval and commercial launch of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders," statesBioXcel Therapeutics’ CEO Vimal Mehta, Ph.D.BioXcel Therapeutics, a clinical-stage biopharmaceutical company focused on developing transformative medicines in neuroscience and immuno-oncology through artificial intelligence approaches, has hired Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO).
"With over 25 years of commercial and industry expertise across multiple product launches including neuroscience products, Matt will be invaluable in spearheading critical launch initiatives, as well as the planned expansion of BXCL501 in additional indications, settings, and geographies, helping us maximize the potential of our AI-driven pipeline and R&D capabilities," adds Mehta.
“I am thrilled to join BioXcel Therapeutics at such an important time, and I look forward to being part of efforts to bring BXCL501 to fill the unmet medical need for millions of patients managing acute agitation associated with schizophrenia and bipolar disorders,” states Mr. Wiley. “The company’s AI-driven approach to drug development represents a novel way of identifying, developing and commercializing transformative neuroscience therapeutics, and I'm excited to join the leadership team in driving this innovative vision.”
Mr. Wiley offers extensive experience in sales, marketing, and strategy from many specialist product launches. He joins BioXcel Therapeutics from VYNE Therapeutics, where he served as Chief Commercial Officer, directing all commercial objectives for the company's first two dermatology treatments, AMZEEQ® and ZILXI®. Before this, he served as Vice President of Marketing and Business Unit Lead for Jazz Pharmaceuticals' sleep medicine unit, where he oversaw the go-to-market strategy and marketing for SUNOSI for the treatment of narcolepsy and sleep apnea and developed a successful growth strategy for XYREM for narcolepsy, which generated $1.4 billion in net revenue during his final year. He previously served as Vice President of Marketing at Azur Pharma, where he was instrumental in the company's launch in the United States and subsequent acquisition by Jazz Pharmaceuticals. Mr. Wiley has also held increasingly responsible positions at Cephalon, Salix Pharmaceuticals, and MGI Pharma. He graduated from Syracuse University with a BA in English.